
1. j virol. 2007 dec;81(24):13801-8. epub 2007 oct 17.

protective immunity pseudomonas aeruginosa induced capsid-modified
adenovirus expressing p. aeruginosa oprf.

worgall s(1), krause a, qiu j, joh j, hackett nr, crystal rg.

author information: 
(1)department genetic medicine, weill medical college cornell university,
new york, new york 10021, usa. geneticmedicine@med.cornell.edu

this study focuses development new clinical vaccine candidate
(adoprf.rgd.epi8) pseudomonas aeruginosa using e1(-) e3(-) adenovirus 
(ad) vector expressing oprf (adoprf.rgd.epi8) modifications ad genome 
providing two capsid changes: (i) modification ad hexon gene to
incorporate immune-dominant oprf epitope (epi8) loop 1 hexon,
enabling repeat administration boost anti-oprf immune response, (ii)
modification fiber gene incorporate integrin-binding rgd sequence to
enhance gene delivery antigen-presenting cells. western analysis confirmed
that adoprf.rgd.epi8 expresses oprf, contains epi8 hexon protein, and
enhances gene transfer dendritic cells compared adoprf, comparable ad
vector expressing oprf unmodified capsid. intramuscular immunization of
c57bl/6 mice adoprf.rgd.epi8 resulted generation anti-oprf
antibodies comparable levels induced following immunization with
adoprf, immunization adoprf.rgd.epi8 associated increased cd4
and cd8 gamma interferon t-cell responses oprf well increased
survival lethal pulmonary challenge agar-encapsulated p. aeruginosa.
importantly, repeat administration adoprf.rgd.epi8 resulted boosting the
humoral anti-oprf response well increased protection, whereas boosting
could achieved repeat administration adoprf. suggests the
capsid-modified adoprf.rgd.epi8 vector effective immunogen compared 
a comparable wild-type ad capsid, making good candidate anti-p.
aeruginosa vaccine.

doi: 10.1128/jvi.01246-07 
pmcid: pmc2168865
pmid: 17942539  [indexed medline]

